IMPACTIVE
Financiado
Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical i...
Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical ingredients.
The environmental impact of the pharmaceutical industry is a huge problem. The production and use of pharmaceuticals cause high CO2 emissions, contamination of soils, biota, and water, and even dangers to human health through carc...
The environmental impact of the pharmaceutical industry is a huge problem. The production and use of pharmaceuticals cause high CO2 emissions, contamination of soils, biota, and water, and even dangers to human health through carcinogenic impurities. Especially the use of solvents is a major problem. The European Green Deal has led to strict regulations on environmental pollution by the pharma industry, causing manufacturers to move outside of the EU due to the high costs associated with green pharma. This results in supply chain fragility and low crisis preparedness in Europe. New methods to produce pharmaceuticals in a green, efficient, and economically friendly way are required.The IMPACTIVE project brings together the expertise and knowledge from two COST Actions and will develop novel green methods to produce active pharmaceutical ingredients (APIs) using mechanochemistry as a disruptive technology (as acknowledged by IUPAC). Mechanochemistry uses mechanical processes, such as ball milling, twin-screw extrusion, resonant acoustic mixing, and spray drying, to induce chemical reactions. The advantages of mechanochemistry include: no solvent use, high efficiency, low costs, and reduced energy use and CO2 emission. Upon completion of the project, we will provide proof-of-concept at a small pilot scale of the use of mechanochemistry to produce 6 APIs from 3 different families of compounds. Based on a recent study, switching to mechanochemistry can reduce terrestrial ecotoxicity and CO2 emissions by more than 85%, while production costs were reduced with 12%. The results of the IMPACTIVE project will thus enable pharmaceutical manufacturers to move back to Europe while minimizing environmental pollution.Through our strong dissemination and communication strategy we will ensure that the project?s results are shared with scientists, the pharmaceutical industry, and stakeholders from regulatory and public authorities to achieve maximum impact.
ver más
Duración del proyecto: 47 meses
Fecha Inicio: 2022-10-01
Fecha Fin: 2026-09-30
Fecha Fin: 2026-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-10-01
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
8M€
Líder del proyecto
UNIVERSITE DE MONTPELLIER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5